Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Compounds with affinity f… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo.

Artikel i vetenskaplig tidskrift
Författare Mikael Landén
O Eriksson
Charlotta Sundblad-Elverfors
Björn Andersch
T Naess?n
Elias Eriksson
Publicerad i Psychopharmacology
Volym 155
Nummer/häfte 3
Sidor 292-8
ISSN 0033-3158
Publiceringsår 2001
Publicerad vid Institutionen för kvinnors och barns hälsa, Avdelningen för obstetrik och gynekologi
Institutionen för fysiologi och farmakologi, Avdelningen för farmakologi
Institutionen för klinisk neurovetenskap, Sektionen för psykiatri
Sidor 292-8
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Adult, Buspirone, administration & dosage, adverse effects, therapeutic use, Double-Blind Method, Female, Humans, Premenstrual Syndrome, drug therapy, psychology, Psychiatric Status Rating Scales, Receptors, Serotonin, drug effects, Serotonin Agonists, administration & dosage, adverse effects, therapeutic use, Treatment Outcome, Triazoles, administration & dosage, adverse effects, therapeutic use
Ämneskategorier Farmakologi och toxikologi

Sammanfattning

RATIONALE: It is well established that serotonin reuptake inhibitors (SRIs) are effective for the treatment of premenstrual dysphoria (PMD), but the receptor subtype(s) mediating this effect of serotonin have yet not been identified. OBJECTIVE: In this trial, the possible efficacy of buspirone, a partial 5HT1A receptor agonist, and nefazodone, a combined SRI and 5HT2 receptor antagonist, was evaluated in women with PMD. METHODS: After a three-menstrual-cycle screening phase, patients were randomised to buspirone (n=19), nefazodone (n=22) or placebo (n=22). During the first two treatment cycles, patients were taking the drug during the luteal phase only (mean +/- SD daily dose of buspirone: 21 +/- 6 mg; nefazodone: 228 +/- 54 mg). During the subsequent two cycles, the medication was taken each day of the menstrual cycle (mean daily dose of buspirone: 27 +/- 10 mg; nefazodone: 304 +/- 95 mg). RESULTS: With respect to self-rated global improvement, buspirone (P<0.001) but not nefazodone was significantly superior to placebo. While buspirone appeared to reduce self-rated irritability (visual analogue scale) more effectively than placebo, other self-rated symptoms did not differ markedly between the groups. The side-effects were mild, and sexual dysfunction was not significantly more common in patients given buspirone or nefazodone than in those given placebo. CONCLUSION: It is suggested that buspirone is mildly effective for premenstrual irritability. In patients experiencing sexual dysfunction when treated with an SRI, buspirone may be a useful alternative.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?